Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy

References

• Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017;24(4):549–553. doi:10.26444/aaem/7594329284222
   PubMed Web of Science ®Google Scholar
• Shachar S, Hurria A, Muss H. Breast cancer in women older than 80 years. J Oncol Pract. 2016;12(2):123–132. doi:10.1200/JOP.2015.01020726869650
   PubMed Web of Science ®Google Scholar
• Liu X, Ma D, Xu X, et al. Genomic landscape and endocrine-resistant subgroup in estrogen receptor-positive, progesterone receptor-negative, and HER2-negative breast cancer. Theranostics. 2018;8(22):6386–6399. doi:10.7150/thno.2916430613307
   PubMed Web of Science ®Google Scholar
• Lin Y, Fu F, Lv J, et al. Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis. Medicine. 2020;99(1):e18445. doi:10.1097/MD.000000000001844531895772
   PubMed Web of Science ®Google Scholar
• Bhusari P, Vatsa R, Singh G, et al. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. Int J Cancer. 2017;140(4):938–947. doi:10.1002/ijc.3050027813061
   PubMed Web of Science ®Google Scholar
• Leung H, Chan A, Muo C, Leung J. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2018;18(2):207–213. doi:10.1080/14737167.2018.138655928965422
   PubMed Web of Science ®Google Scholar
• Barginear M, John V, Budman D. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med. 2013;18:1473–1479.23196784
   PubMed Web of Science ®Google Scholar
• Takahashi M, Takahashi K, Matsumoto S, et al. Low eosinophil percentages as a new predictive marker for infusion reactions due to trastuzumab. Anticancer Res. 2020;40(7):4047–4051.32620651
   PubMed Web of Science ®Google Scholar
• Derakhshani A, Rezaei Z, Safarpour H, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235(4):3142–3156.31566722
   PubMed Web of Science ®Google Scholar
• Hertz D. Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships. Expert Opin Drug Metab Toxicol. 2021;17(2):227–239. doi:10.1080/17425255.2021.185636733401943
   PubMed Web of Science ®Google Scholar
• Gaio E, Conte C, Esposito D, et al. Co-delivery of docetaxel and disulfonate tetraphenyl chlorin in one nanoparticle produces strong synergism between chemo- and photodynamic therapy in drug-sensitive and -resistant cancer cells. Mol Pharm. 2018;15(10):4599–4611.30148955
   PubMed Web of Science ®Google Scholar
• Hendrikx J, Stuurman F, Song J, et al. No relation between docetaxel administration route and high-grade diarrhea incidence. Pharmacol Res Perspect. 2020;8(4):e00633.32725720
   PubMed Web of Science ®Google Scholar
• Lee C, Zhou K, Young W, et al. Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: a retrospective cohort study on duration of prophylactic GCSF administration. Support Care Cancer. 2020;28(8):3801–3812.31832822
   PubMed Web of Science ®Google Scholar
• Rodallec A, Brunel J, Giacometti S, et al. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. Int J Nanomedicine. 2018;13:3451–3465.29950829
   PubMed Web of Science ®Google Scholar
• Jin Y, Hua Q, Zheng J, et al. Diagnostic value of ER, PR, FR and HER-2-targeted molecular probes for magnetic resonance imaging in patients with breast cancer. Cell Physiol Biochem. 2018;49(1):271–281.30138940
   PubMedGoogle Scholar
• Mu Y, He J, Yan R, Hu X, Liu H and Hao Z. IGF-1 and VEGF can be used as prognostic indicators for patients with uterine fibroids treated with uterine artery embolization. Exp Ther Med. 2016;11:645–649.
   Google Scholar
• Frappaz D, Bonneville-Levard A, Ricard D, et al. Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias. Support Care Cancer. 2021;29(4):1883–1891.32789684
   PubMed Web of Science ®Google Scholar
• Adamo B, Bellet M, Paré L, et al. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Res. 2019;21(1):108.31533777
   PubMed Web of Science ®Google Scholar
• Orlando L, Lorusso V, Giotta F, et al. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: a Phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). Breast. 2020;53:18–22.32540553
   PubMed Web of Science ®Google Scholar
• Tang J, Luo Y, Tian Z, et al. TRIM11 promotes breast cancer cell proliferation by stabilizing estrogen receptor α. Neoplasia. 2020;22(9):343–351.32599554
   PubMed Web of Science ®Google Scholar
• Gao Y, Song P, Li H, Jia H, Zhang B. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations. BMC Cancer. 2017;17(1):484. doi:10.1186/s12885-017-3474-328705152
   PubMed Web of Science ®Google Scholar
• Dolscheid-Pommerich R, Keyver-Paik M, Hecking T, et al. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers. Tumor Biol. 2017;39(10):1010428317730246.
   Google Scholar
• Nam S, Lim W, Jeong J, et al. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean breast cancer society registry. Breast Cancer Res Treat. 2019;177(3):669–678.31312932
   PubMed Web of Science ®Google Scholar
• Chen R, Jiang C, Zhu Q, et al. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer. Medicine. 2020;99(29):e21231.32702897
   PubMed Web of Science ®Google Scholar
• Hong T, Liu A, Cai D, et al. Preoperative serum C-reactive protein levels and early breast cancer by BMI and menopausal status. Cancer Invest. 2013;31(4):279–285.23627410
   PubMed Web of Science ®Google Scholar
• Rivas M, Tkach M, Beguelin W, et al. Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast Cancer Res Treat. 2010;122(1):111–124.19760502
   PubMed Web of Science ®Google Scholar
• Lemos L, Victorino V, Herrera A, et al. Trastuzumab-based chemotherapy modulates systemic redox homeostasis in women with HER2-positive breast cancer. Int Immunopharmacol. 2015;27(1):8–14.25937481
   PubMed Web of Science ®Google Scholar
• Abi Jaoude J, de Azambuja E, Makki M, et al. Post-mastectomy radiation therapy in human epidermal growth factor receptor 2 positive breast cancer patients: analysis of the HERA trial. Int J Radiat Oncol Biol Phys. 2020;106(3):503–510.31654782
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ohtani S, Nagai S, et al. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study. Breast Cancer Res Treat. 2021;185(1):125–134.32920732
   PubMed Web of Science ®Google Scholar
• Konieczny M, Cipora E, Roczniak W, Babuśka-Roczniak M, Wojtaszek M. Impact of time to initiation of treatment on the quality of life of women with breast cancer. Int J Environ Res Public Health. 2020;17(22):8325. doi:10.3390/ijerph17228325
   PubMed Web of Science ®Google Scholar